DXCM

SEC source: 0001093557-18-000060 · edgardoc.xml · nonDerivative · entry 1

ACE HEATHER S · CIK 0001610762 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,232

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 65,306 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,588 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 20,625 of which were granted on August 22, 2016 and shall vest through August 22, 2020.

SEC source: 0001093557-18-000059 · edgardoc.xml · nonDerivative · entry 3

Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,180

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 29,391 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 7,574 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 5,000 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000059 · edgardoc.xml · nonDerivative · entry 2

Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,509

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 29,391 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 7,574 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 5,000 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000059 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,071

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 29,391 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 7,574 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 5,000 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000058 · edgardoc.xml · nonDerivative · entry 3

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,878

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 56,182 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 15,422 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 10,667 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000058 · edgardoc.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,284

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 56,182 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 15,422 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 10,667 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000058 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,155

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 56,182 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 15,422 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 10,667 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,830

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 2

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,051

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,740

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,567

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,031

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000056 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,252

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000055 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,953

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019.

SEC source: 0001093557-18-000054 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,674

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 47,087 unvested restricted stock units which were granted on March 8, 2018 and shall vest through March 8, 2021.

SEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,171

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,468

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,751

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000042 · edgardoc.xml · nonDerivative · entry 1

MOY JEFFREY · CIK 0001446422 · SVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,834

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 55,681 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,588 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 11,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000041 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP, Quality & Regulatory Afrs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,228

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019.

SEC source: 0001093557-18-000040 · edgardoc.xml · nonDerivative · entry 1

ACE HEATHER S · CIK 0001610762 · SVP Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,859

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 65,306 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,588 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 20,625 of which were granted on August 22, 2016 and shall vest through August 22, 2020.

SEC source: 0001093557-18-000039 · edgardoc.xml · nonDerivative · entry 1

Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,258

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 100,860 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 62,358 of which were granted on September 7, 2017 and shall vest through September 7, 2021.

SEC source: 0001093557-18-000038 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,928

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000037 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,371

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000036 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,086

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000035 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,948

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 29,391 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 7,574 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 5,000 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000034 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,331

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 56,182 unvested restricted stock units, 30,093 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 15,422 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 10,667 of which were granted on March 8, 2016 shall vest through March 8, 2019.

SEC source: 0001093557-18-000033 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 531,646

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 47,087 unvested restricted stock units which were granted on March 8, 2018 and shall vest through March 8, 2021.

SEC source: 0001093557-18-000032 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,737

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

SEC source: 0001093557-18-000020 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 13,972

F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $55.80 to $56.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-18-000009 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 20,882

F1 · shares: On December 5, 2017, Mr. Gregg adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Gregg. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $55.64 and $56.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Gregg Family Trust U/A/D 12/23/1998, with respect to which the reporting person is a trustee.

SEC source: 0001093557-18-000007 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 15,610

F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $54.51 to $54.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-18-000005 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 30,882

F1 · shares: On December 5, 2017, Mr. Gregg adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Gregg. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $56.44 and $57.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Gregg Family Trust U/A/D 12/23/1998, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000243 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 17,245

F1 · price: This transaction was executed in multiple trades at prices ranging from $56.16 to $56.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000241 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,826

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017.

F2 · price: This transaction was executed in multiple trades at prices ranging from $58.01 to $59.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000240 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,547

F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000237 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,426

F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.46. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000236 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,792

F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000233 · edgardoc.xml · nonDerivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 13,143

F1 · price: This transaction was executed in multiple trades at prices ranging from $54.95 to $54.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000231 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 18,880

F1 · price: This transaction was executed in multiple trades at prices ranging from $55.34 to $55.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000227 · edgardoc.xml · nonDerivative · entry 1

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 23,095

F1 · price: This transaction was executed in multiple trades at prices ranging from $54.54 to $54.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000229 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,826

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017.

F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000225 · edgardoc.xml · nonDerivative · entry 1

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 58,502

F1 · ownership.nature: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000223 · edgardoc.xml · nonDerivative · entry 1

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 33,502

F1 · ownership.nature: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000207 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 20,515

F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $44.59 to $45.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000205 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 22,150

F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $69.56 to $70.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000204 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,326

F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $69.59 to $70.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000201 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,826

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017.

F2 · price: This transaction was executed in multiple trades at prices ranging from $69.02 to $69.57. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000199 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,826

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000199 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,753

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.